Category Archives: Ulcerative Colitis

Ulcerative colitis and Crohns disease are both forms of inflammatory bowel disease. In both conditions, a persons intestinal tract regularly becomes inflamed. Continue reading →

This transcript has been edited for clarity. Hello Continue reading →

PARIS, FRANCE / ACCESSWIRE / May 24, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today the suspension of the trading of its shares until the publication of the results of its phase 2b study for the treatment of ulcerative colitis with ABX464. The Company expects to publish a press release on this topic today after market closure (May 24, 2021) Continue reading →

COULD GET ONE AND CONTRIBUTE TO A GOOD CAUSE. FOUR-YEAR-OLD ALEX KYRPYCH, WITH THE HELP OF HER MOM CAROYLN, S UP THIS ITALIAN ICE STAND IN WESTWOOD. ALL THE MONEY RAISED GOES TO SUPPORT THE CROHNS & COLITIS FOUNDATION OF NEW ENGLAND Continue reading →

Fatigue is a common condition for patients with inflammatory bowel disease (IBD), but there are various trends that show whether a Crohns disease or ulcerative colitis patient is at a higher risk for fatigue. A team, led by Miguel Regueiro, MD, Cleveland Clinic, assessed the prevalence of fatigue for Crohns disease and ulcerative colitis patients and evaluated the association of fatigue with disease activity and patient-reported outcomes. Continue reading →

In new data presented during the Digestive Disease Week 2021 Virtual Meeting shows the safety and efficacy of vedolizumab for patients with inflammatory bowel disease (IBD). Continue reading →

SPRING HOUSE, Pa., May 23, 2021 /PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC),1-4 including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-nave patients with moderately to severely active CD, although the primary endpoint of statistical superiority versus adalimumab was not demonstrated.1 These head-to-head data are one of 20 abstracts Janssen presented from the Company's gastroenterology pipeline and portfolio at DDW Virtual 2021, which took place May 21-23.1-4 "As the first head-to-head study of biologic therapiesin Crohn's disease, SEAVUE is filling an important knowledge gap in the gastrointestinal community," said Bruce E. Sands, M.D., M.S., Chief of the Dr. Henry D Continue reading →

While previous studies on ant-TNF medications, such as adalimumab (ADA), have showed increased risk of infection in patients with inflammatory bowel disease (IBD), there is limited data on safety outcomes stratified by trough levels. Investigators, led by Samantha Ellison, MD of the University of Pennsylvania, found that in the cohort of IBD patients, higher ADA trough concentration did not have an association with a higher likelihood of adverse events. The study was presented online at the 2021 Digestive Disease Week (DDW) Virtual Meeting Continue reading →

Irritable bowel syndrome, or IBS, is an extremely common medical condition and the prevalence of IBS in the United States is among the highest in the world. Bowel inflammation is a known risk factor for IBS. Reducing bowel inflammation can alleviate the symptoms of IBS Continue reading →

DURHAM, N.C., May 23, 2021 /PRNewswire/ -- Research presented today at Digestive Disease Week (DDW) 2021 evaluated the prevalence and predictors of immunomodulator use as concomitant therapy with two commonly prescribed biologics, vedolizumab (Entyvio) or ustekinumab (Stelara), in patients with inflammatory bowel disease (IBD). Data from Target RWE's TARGET-IBD large longitudinal cohort Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort was selected for the Poster of Distinction Award Continue reading →